Author + information
- Caihong Qu,
- Jieming Zhu,
- Xiaoyan Li and
- Ling Tao
In order to investigate the clinical efficacy of Shuganjieyu Capsules and Flupentixol and Melitracen Tablets in the treatment of cardiac neurosis.
Totally 83 aged patients which was ruled out coronary artery disease and diagnosed with cardiac neurosis in the Third Affiliated Hospital of Sun Yat-sen University from January 2014 to December 2015 were randomly divided into 2 groups, Shuganjieyu Capsules treatment group (n=42) and Flupentixol and Melitracen Tablets control group (n=42). Shuganjieyu Capsules treatment group received 2 capsules twice a day and Flupentixol and Melitracen Tablets control group received 1 tablet once a day for 8 weeks. Before and after treatment somatic symptoms were observed, electrocardiography was examined and Hamilton Depression Scale was used in both groups.
After treatment somatic symptoms in both groups were alleviated, electrocardiography results improved and the test scores declined in Shuganjieyu Capsules treatment group (7.5±3.5) vs. Flupentixol and Melitracen Tablets control group (7.8±2.8), respectively, which had no significant difference (P>0.05) between them.
As a Chinese patent medicine, Shuganjieyu Capsules can play an active role in improving the patients' depression, anxiety, chest tightness, palpitation, and so on, which is not inferior to the Western medicine.